Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel / B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watt, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. Van De Sluis, M. Taskinen, L. Tokgözoǧlu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 38:32(2017 Aug 21), pp. 2459-2472. [10.1093/eurheartj/ehx144]

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

A.L. Catapano
Ultimo
2017

Abstract

Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
English
Atherosclerosis; Cardiovascular disease; Causality; Clinical trials; Ezetimibe; Low-density lipoprotein; Mendelian randomization; PCSK9; Recommendations; Statin; Cardiology and Cardiovascular Medicine
Settore BIO/14 - Farmacologia
Articolo
Esperti anonimi
Ricerca applicata
Pubblicazione scientifica
21-ago-2017
Oxford University Press
38
32
2459
2472
14
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel / B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watt, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. Van De Sluis, M. Taskinen, L. Tokgözoǧlu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 38:32(2017 Aug 21), pp. 2459-2472. [10.1093/eurheartj/ehx144]
open
Prodotti della ricerca::01 - Articolo su periodico
26
262
Article (author)
Periodico con Impact Factor
B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watt, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. Van De Sluis, M. Taskinen, L. Tokgözoǧlu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano
File in questo prodotto:
File Dimensione Formato  
LDL_causes_ASCVD.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 823.62 kB
Formato Adobe PDF
823.62 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/548996
Citazioni
  • ???jsp.display-item.citation.pmc??? 850
  • Scopus 2176
  • ???jsp.display-item.citation.isi??? 1972
social impact